PYRUKYND Drug Patent Profile

When do Pyrukynd patents expire, and when can generic versions of Pyrukynd launch?

Pyrukynd is a drug marketed by Agios Pharms Inc and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-one patent family members in forty-six countries.

The generic ingredient in PYRUKYND is mitapivat sulfate. One supplier is listed for this compound. Additional details are available on the mitapivat sulfate profile page.

DrugPatentWatch^® Generic Entry Outlook for Pyrukynd

Pyrukynd was eligible for patent challenges on February 17, 2026.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 11, 2035. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for PYRUKYND

International Patents:	191
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	33
Drug Prices:	Drug price information for PYRUKYND
What excipients (inactive ingredients) are in PYRUKYND?	PYRUKYND excipients list
DailyMed Link:	PYRUKYND at DailyMed

See drug prices for PYRUKYND

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for PYRUKYND

Constraining patent/regulatory exclusivity:

RE49582

NDA:

216196

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for PYRUKYND

Drug Class	Pyruvate Kinase Activator
Mechanism of Action	Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C8 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 3A Inducers P-Glycoprotein Inhibitors Pyruvate Kinase Activators UGT1A1 Inducers

Paragraph IV (Patent) Challenges for PYRUKYND

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PYRUKYND	Tablets	mitapivat sulfate	5 mg, 20 mg and 50 mg	216196	1	2026-02-17

US Patents and Regulatory Information for PYRUKYND

PYRUKYND is protected by nine US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent RE49582.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-003	Feb 17, 2022		RX	Yes	Yes
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-003	Feb 17, 2022		RX	Yes	Yes	10,632,114
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-003	Feb 17, 2022		RX	Yes	Yes
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-003	Feb 17, 2022		RX	Yes	Yes	11,234,976
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-001	Feb 17, 2022		RX	Yes	No	11,878,049
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-002	Feb 17, 2022		RX	Yes	No	11,234,976

International Patents for PYRUKYND

When does loss-of-exclusivity occur for PYRUKYND?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

European Patent Office

Finland

France

Hungary

India

Israel

Japan

Lithuania

Malaysia

Mexico

New Zealand

Nicaragua

Norway

Peru

Poland

Portugal

Russian Federation

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering PYRUKYND around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2012250688	Pyruvate kinase activators for use in therapy
Australia	2017221860	PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY
Australia	2020200700	PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY
Brazil	112013028422	ativadores de piruvato cinase para uso em terapia
Canada	2834602	ACTIVATEURS DE LA PYRUVATE KINASE DESTINES A ETRE UTILISES EN THERAPIE (PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY)
Canada	3088328	ACTIVATEURS DE LA PYRUVATE KINASE DESTINES A ETRE UTILISES EN THERAPIE (PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY)

Supplementary Protection Certificates for PYRUKYND

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2448582	301230	Netherlands		PRODUCT NAME: MITAPIVAT, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER MITAPIVATSULFAAT; REGISTRATION NO/DATE: EU/1/22/1662 20221110
2448582	CA 2023 00014	Denmark		PRODUCT NAME: MITAPIVAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER MITAPIVATSULFAT; REG. NO/DATE: EU/1/22/1662 20221110
2448582	2023C/517	Belgium		PRODUCT NAME: MITAPIVAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE SULFATE DE MITAPIVAT; AUTHORISATION NUMBER AND DATE: EU/1/22/1662 20221110
2448582	LUC00306	Luxembourg		PRODUCT NAME: MITAPIVAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR MITAPIVAT SULFATE; AUTHORISATION NUMBER AND DATE: EU/1/22/1662 20221110
2448582	PA2023513	Lithuania		PRODUCT NAME: MITAPIVATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC MITAPIVATO SULFATAS; REGISTRATION NO/DATE: EU/1/22/1662 20221109
2448582	CR 2023 00014	Denmark		PRODUCT NAME: MITAPIVAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER MITAPIVATSULFAT; REG. NO/DATE: EU/1/22/1662 20221110

PYRUKYND (mitapivat) Market Dynamics and Financial Trajectory: Sales Trends, Pricing, Access, and Patent-Driven Generics Risk

Last updated: June 10, 2026

Executive summary: PYRUKYND (mitapivat) is a premium-priced therapy for pyruvate kinase deficiency (PKD) with an income profile dominated by (i) the pace of specialist adoption in hemolytic PKD and (ii) payer coverage decisions that determine net price versus list price. Near-term revenue trajectory is primarily constrained by treatable patient counts and by the manufacturing and contracting cadence of a single-source product while commercial growth depends on cycle times from diagnosis to treatment initiation. Competitive and exclusivity-driven risk is primarily medium because PYRUKYND faces no immediate broad generic substitution pathway typical of small-molecule LCM products, but patient attrition, payer pushback, and next-generation PKD treatments can still shift share over time.

---

What is the current sales trajectory for PYRUKYND (mitapivat) and how fast is uptake?

PYRUKYND commercialization dynamics track three bottlenecks: diagnosis rate, hematology referral patterns, and prior authorization cycle times. Mitapivat’s addressable population is limited to patients with PKD who meet clinical and labeling criteria, so revenue growth typically shows a “stepwise” pattern as payers expand coverage and as prescribers gain confidence in efficacy and tolerability.

What to watch in the financial trajectory

• Net revenue growth vs. headcount of treated patients: Revenue can rise with stable patient counts if net price improves; revenue can fall even if demand grows if rebates and access hurdles rise.
• Reimbursement friction: High prior-auth denial rates and slow appeals push out starts, flattening quarterly starts and shifting revenue into later periods.
• Seasonality tied to lab monitoring: PKD follow-up schedules affect dose continuity and switching, which feed into quarterly prescription fill and persistence metrics.

Commercial inflection points that typically accelerate revenue

• Formal payer policy updates expanding coverage.
• Expanded sites of care and improved distribution reliability.
• Clearer payer acceptance in value-based contracting, if present, tied to hemolysis lab markers.

---

How do PYRUKYND list price, net price, and payer access shape financial performance?

Mitapivat is positioned as a specialty therapy with high list price. Financial trajectory therefore hinges on net price after rebates, patient assistance, and administrative spend. Even when demand is stable, changes in rebate rates and access terms can move reported revenue.

Key drivers of net price for PYRUKYND

• Formulary tiering: Preferred placement generally increases treated-share at the cost of higher manufacturer rebates if payers require volume commitments.
• Utilization management: Prior authorization criteria aligned to labeling can reduce access delays but also increase denial risk if documentation is incomplete.
• Member cost-share design: High coinsurance can depress persistence; patient assistance can offset but may shift net revenue through reimbursement structure.

Evidence-based pattern used for specialty drugs

• Early quarters often show higher gross-to-net pressure as payers learn utilization patterns.
• Once claims data mature, manufacturers can renegotiate rebate bands or narrow coverage restrictions, improving net revenue stability.

---

When does PYRUKYND face exclusivity and how does that affect long-term revenue?

Long-term revenue risk comes from exclusivity end dates and patent estate strength rather than from immediate generic substitutes. For mitapivat, revenue risk is mediated by how long the core claims remain enforceable for:

• active ingredient composition
• key formulations
• dosing regimens
• method-of-use (including PKD-related clinical outcomes)

Revenue implications

• If exclusivity remains intact through later periods, the competitive threat curve rises slowly, typically showing first pressure from pipeline entrants rather than from “instant” generic substitution.
• If later-stage patent challenges succeed on narrower claim sets, biosimilar-like competition is not relevant, but a launch of infringing generics could still hit share and price.

---

What patents protect PYRUKYND and which families control the commercial runway?

The commercial runway for mitapivat depends on multiple layers:

• patent claims that read on the drug substance and/or intermediates
• formulation or manufacturing method claims
• method-of-use claims tied to PKD phenotype, hemolysis response markers, or dosing

What matters for revenue

• Claim coverage that prevents copycat dosing or labeling carve-outs.
• Ability to obtain injunctions or secure settlements that delay market entry.

How to connect the estate to financial trajectory

• Strong, broad claims correlate with lower probability of near-term price compression.
• Narrower claims increase the risk that generic or authorized competitors can design around.

---

Is there any Paragraph IV or generic entry risk for PYRUKYND?

For a premium specialty small-molecule, generic substitution is the principal driver of price erosion. The generic entry risk timing for PYRUKYND depends on the patent landscape and the regulatory pathway used for any abbreviated filing.

How the threat typically shows up in earnings

• Revenue begins to flatten before entry as wholesalers pull forward demand or as payers restrict usage.
• After entry, net price drops quickly due to formulary re-tiering and rebate renegotiations, usually outpacing demand recovery.

---

How strong is PYRUKYND’s patent estate versus likely design-around strategies?

Mitapivat’s patent strength should be assessed by whether the key claims are composition-based or method-of-use based. Composition-based coverage is harder to design around because alternate salts, polymorphs, or dosing schedules may not avoid infringement if claims are drafted broadly.

Design-around risks

• Alternate formulations that still use the same active ingredient.
• Alternative dosing schedules that attempt to avoid method-of-use claims.
• Different patient selection if method-of-use claims are tied to specific biomarker thresholds.

---

What litigation affects PYRUKYND’s market access and launch timing for competitors?

Patent litigation impacts market timing through:

• injunction outcomes
• settlement agreements that establish delayed entry dates
• scope of “carve-outs” that allow partial competition

Financial linkage

• A settlement that delays entry supports predictable revenue over the settlement term.
• A loss or injunction reversal accelerates competitive entry and forces rebate and price changes.

---

What is the Orange Book status of PYRUKYND and what does it imply for generic risk?

The Orange Book status drives investor and payer expectations for generic timing. A robust Orange Book listing across multiple patent types tends to delay entry, while sparse listings increase entry probability.

What to look for

• Number of listed patents and patent types (drug substance, drug product, and method-of-use).
• Time-to-expiration distribution across the families.
• Whether any patents have been delisted or narrowed.

---

Which companies are challenging PYRUKYND and what settlement outcomes matter most?

Competitor risk depends on who files first and on the leverage position established by patent holders during litigation. Market share impact depends on:

• whether challengers win at the district court or Federal Circuit
• whether parties enter a global settlement
• whether settlements permit “at-risk” launches or delayed-launch windows

Revenue relevance

• First challenger outcomes are disproportionately important because they set precedents for pricing pressure and payer contracting.

---

How does PYRUKYND compare with competing therapies for pyruvate kinase deficiency (PKD)?

PYRUKYND’s competitive position depends on efficacy endpoints, dosing convenience, safety profile, and payer adoption.

Commercial comparison variables

• Response depth on hemolysis markers and transfusion burden (when applicable).
• Persistence and discontinuation drivers (adverse events, inadequate response).
• Treatment burden and monitoring requirements.
• Real-world dosing stability and adherence.

---

What is the reimbursement landscape for mitapivat in PKD and how does it vary by geography?

Specialty drugs can show meaningful net revenue variation across geographies due to:

• national health technology assessment outcomes
• managed entry agreements and budget caps
• prescribing restrictions and diagnostic confirmation requirements

Geographic financial drivers

• Tender or reference pricing in markets with external price referencing.
• Uptake influenced by reimbursement committee timetables.
• Differences in patient access routes affecting time-to-treatment and persistence.

---

How does PYRUKYND manufacturing capacity and supply continuity affect sales and financials?

Supply reliability is a direct driver of realized revenue in specialty drugs. Disruptions lead to:

• delayed treatment starts
• dose interruptions
• payer disputes and inventory corrections

Financial impacts

• Lost demand during shortages can be difficult to recapture later because of payer churn and patient switching.
• Quality events typically trigger additional administrative costs and lead to revenue volatility.

---

What generic entry scenario would most reduce PYRUKYND revenue and how quickly?

The most adverse scenario for revenue is rapid formulary switch plus rebate renegotiation after a generic or authorized competing entry. The pace of erosion depends on:

• how quickly payers remove PYRUKYND from preferred tiers
• the availability of alternative products at comparable access terms
• prescriber comfort with switching

Typical revenue effect pattern for specialty small-molecules

• First year after entry: revenue drops sharply, often partially offset by treatment-naïve demand that continues to exist in the addressable population.
• Second year: net price pressure deepens if multiple competitors enter and if payers harden rebate demands.

---

What is the overall revenue exposure for PYRUKYND and what levers mitigate downside?

PYRUKYND revenue exposure is primarily tied to:

• continued expansion in treated patients
• sustained net price through payer contracting
• persistence and reduced discontinuation

Downside mitigants

• Stronger label awareness and clinician guidance that reduces initiation friction.
• Contracting strategies that lock rebate bands or include patient-share mechanics.
• Extended access and payer partnerships that reduce denials.

---

Key tables and structured view

PYRUKYND financial trajectory map (business-focused)

Revenue driver	Primary metric to track	What it does to trajectory	What to infer commercially
Uptake	New starts per quarter	Accelerates or delays top-line growth	Measures adoption and access speed
Net price	Gross-to-net ratio; payer mix	Stabilizes or erodes revenue	Indicates formulary positioning strength
Persistence	Discontinuation rate; dose continuity	Smooths revenue across quarters	Predicts life-cycle curve
Contracting	Rebate terms; value-based deals	Moves realized revenue	Shows payer leverage and manufacturer negotiation power
Supply	Fill rate and backorders	Prevents lost revenue	Assesses operational risk
Competitive pressure	Formulary tier changes	Drives market share shifts	Indicates speed of price erosion risk

---

Key Takeaways

• PYRUKYND’s revenue trajectory is dominated by treated-patient uptake and net-price realization rather than by broad market expansion.
• Financial performance is sensitive to reimbursement friction, including prior-authorization and rebate structure.
• Long-term downside is tied to the patent estate and litigation outcomes that determine if and when competition can launch; generic risk is not a near-term certainty but remains the principal mechanism for rapid price erosion.
• Supply continuity and persistence are leading operational levers that prevent quarter-to-quarter revenue volatility.

---

FAQs

1. What payer actions most influence PYRUKYND net revenue—formulary tiering or prior authorization?
2. How does time-to-treatment after diagnosis affect PYRUKYND annual revenue growth?
3. What patent estate features would delay generic entry for mitapivat the longest?
4. How quickly do net price and market share typically change after a specialty small-molecule competitor launches?
5. Which real-world discontinuation factors most affect PYRUKYND persistence and revenue stability?

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Approval Packages: PYRUKYND (mitapivat). U.S. Food and Drug Administration.
3. Company filings and investor presentations for PYRUKYND commercialization updates (most recent available).

DrugChatter Q&A for PYRUKYND

Agios pharmaceuticals pyrukynd fda pdufa extension 2026?
Is pyrukynd for pk deficiency?
What is the dosing for Pyrukynd?